Kimberly-Clark is buying Tylenol maker Kenvue in a cash and stock deal worth about $48.7 billion, creating a massive consumer health goods company.

Kenvue shareholders will receive $3.50 per share in cash and 0.14625 Kimberly-Clark shares for each Kenvue share held at closing. That amounts to $21.01 per share, based on the closing price of Kimberly-Clark shares on Friday.

RELATED STORY | Trump links Tylenol in pregnancy to autism despite contested science

Kimberly-Clark shareholders are expected to own about 54% of the combined company. Kenvue shareholders will own about 46%.

The deal is expected to close in the second half of next year. It still needs approval from shareholders of both companies.

President Donald Trump recently thrust Tylenol into the national spotlight. In September

See Full Page